［1］ GRÜENTZIG A R，SENNING A，SIEGENTHALER W E.Nonoperative dilatation of coronary-artery stenosis：percutaneous transluminal coronary angioplasty［J］.N Engl J Med，1979，301（2）：61-68.

［2］ GRÜENTZIG A R，KING S B 3rd，SCHLUMPF M，et al.Long-term follow-up after percutaneous transluminal coronary angioplasty.The early Zurich experience［J］.N Engl J Med，1987，316（18）：1127-1132.

［3］ ERBEL R，HAUDE M，HÖPP H W，et al.Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty.Restenosis Stent Study Group［J］.N Engl J Med，1998，339（23）：1672-1678.

［4］ NAKAZAWA G，FINN A V，JONER M，et al.Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients：an autopsy study［J］.Circulation，2008，118（11）：1138-1145.

［5］ MOSES J W，LEON M B，POPMA J J，et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery［J］.N Engl J Med，2003，349（14）：1315-1323.

［6］ STONE G W，ELLIS S G，CANNON L，et al.Comparison of a polymer-based paclitaxeleluting stent with a bare metal stent in patients with complex coronary artery disease：a randomized con trolled trial［J］.JAMA，2005，294（10）：1215-1223.

［7］ CAMENZIND E，STEG P G，WIJNS W.Stent thrombosis late after implantation of firstgeneration drug-eluting stents：a cause for con cern［J］.Circulation，2007，115（11）：1440-1455.

［8］ RICHELSEN R K，OVERVAD T F，JENSEN S E.Drug-eluting balloons in the treatment of coronary de novo lesions：a comprehensive review［J］.Cardiol Ther，2016，5（2）：133-1360.

［9］ BHATT D L.Intensifying platelet inhibition—navigating between Scylla and Charybdis［J］.N Engl J Med，2007，357（20）：2078-2081.

［10］ LEMOS P A，HOYE A，GOEDHART D，et al.Clinical，angiographic，and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients：an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital（RESEARCH） study［J］.Circulation，2004，109（11）：1366-1370.

［11］ SCHELLER B，SPECK U，ABRAMJUK C，et al.Paclitaxel balloon coating，a novel method for prevention and therapy of restenosis［J］.Circulation，2004，110（7）：810-814.

［12］ GRAY W A，GRANADA J F.Drug-coated balloons for the prevention of vascular restenosis［J］.Circulation，2010，121（24）：2672-2680.

［13］ SCHELLER B，SPECK U，ROMEIKE B，et al.Contrast media as a carrier for local drug delivery：successful inhibition of neointimal proliferation in the porcine coronary stent model［J］.Eur Heart J，2003，24（15）：1462-1467.

［14］ SCHELLER B，SPECK U，SCHMITT A，et al.Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation［J］.J Am Coll Cardiol，2003，42（8）：1415-1420.

［15］ 鲁景元，徐文健，楼文胜，等.药物涂层球囊概述及其在外周动脉疾病治疗中的应用进展［J］.现代生物学进展，2017，17（30）：5993-6000.

［16］ ALBRECHT T，SPECK U，BEIER C，et al.Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine［J］.Invest Radiol，2007，42（8）：579-585.

［17］ LEE J，LEE S C，ACHARYA G，et al.Hydrotropic solubilization of paclitaxel：analysis of chemical structures for hydrotropic property［J］.Pharm Res，2003，20（7）：1022-1030.

［18］ LOVICH M A，CREEL C，HONG K，et al.Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel［J］.J Pharm Sci，2001，90（9）：1324-1335.

［19］ PAPAFAKLIS M I，CHATZIZISIS Y S，NAKA K K，et al.Drug-eluting stent restenosis：effects of drug type，release kinetics hemodynamics and coating strategy［J］.Pharmacol Ther，2012，134（1）：43-53.

［20］ BONDESSON P，LAGERQVIST B，JAMES S K，et al.Comparison of two drug-eluting balloons：a report from the SCAAR registry［J］.EuroIntervention，2012，8（4）：444-449.

［21］ 《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识［J］.中国介入心脏病学杂志，2016，24（2）：61-67.

［22］ KELSCH B，SCHELLER B，BIEDERMANN M，et al.Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model［J］.Invest Radiol，2011，46（4）：255-263.

［23］ YAZDANI S K，PACHECO E，NAKANO M，et al.Vascular，downstream，and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model［J］.Catheter Cardiovasc Interv，2014，83（1）：132-140.

［24］ GRANADA J F，STENOIEN M，BUSZMAN P P，et al.Mechanisms of tissue uptake and retention of paclitaxel-coated balloons：impact on neointimal proliferation and healing［J］.Open Heart，2014，1（1）：e000117.

［25］ CHENG Y，LEON M B，GRANADA J F.An update on the clinical use of drug-coated balloons in percutaneous coronary interventions［J］.Expert Opin Drug Deliv，2016，13（6）：859-872.

［26］ CREMERS B，SPECK U，KAUFELS N，et al.Drug-eluting balloon：very short-term exposure and overlapping［J］.Thromb Haemost，2009，101（1）：201-206.

［27］ CREMERS B，KELSCH B，CLEVER Y P，et al.Inhibition of neointimal proliferation after bare metal stent implantation with low-pressure drug delivery using a paclitaxelcoated balloon in porcine coronary arteries［J］.Clin Res Cardiol，2012，101（5）：385-391.

［28］ SCHELLER B，HEHRLEIN C，BOCKSCH W，et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter［J］.N Engl J Med，2006，355（20）：2113-2124.

［29］ UNVERDORBEN M，VALLBRACHT C，CREMERS B，et al.Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis［J］.Circulation，2009，119（23）：2986-2994.

［30］ RITTGER H，BRACHMANN J，SINHA A M，et al.A randomized，multicenter，singleblinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis：the PEPCAD-DES study［J］.J Am Coll Cardiol，2012，59（15）：1377-1382.

［31］ BYRNE R A，NEUMANN F J，MEHILLI J，et al.Paclitaxel-eluting balloons，paclitaxeleluting stents，and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent（ISAR-DESIRE 3）：a randomised，open-label trial［J］.Lancet，2013，381（9865）：461-467.

［32］ XU B，GAO R，WANG J，et al.A prospective，multicenter，randomized trial of paclitaxelcoated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent instent restenosis：results from the PEPCAD China ISR trial［J］.JACC Cardiovasc Interv，2014，7（2）：204-211.

［33］ ALFONSO F，PÉREZ-VIZCAYNO M J，CÁRDENAS A，et al.A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stentin-stent restenosis：the RIBSⅤ Clinical Trial（Restenosis Intra-stent of Bare Metal Stents：paclitaxel-eluting balloon vs.everolimus-eluting stent）［J］.J Am Coll Cardiol，2014，63（14）：1378-1386.

［34］ ALFONSO F，PÉREZ-VIZCAYNO M J，CÁRDENAS A，et al.A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents：the RIBS Ⅳ randomized clinical trial［J］.J Am Coll Cardiol，2015，66（1）：23-33.

［35］ ADRIAENSSENS T，DENS J，UGHI G，et al.Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs.everolimus-eluting stents for instent restenosis：the SEDUCE（Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis） randomised clinical trial［J］.EuroIntervention，2014，10（4）：439-448.

［36］ WINDECKER S，KOLH P，ALFONSO F，et al.2014 ESC/EACTS Guidelines on myocardial revascularization：The Task Force on Myocardial Revascularization of the European Society of Cardiology （ESC） and the European Association for Cardio-Thoracic Surgery（EACTS） Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions（EAPCI）［J］.Eur Heart J，2014，35（37）：2541-2619.

［37］ UNVERDORBEN M，KLEBER F X，HEUER H，et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter［J］.Clin Res Cardiol，2010，99（3）：165-174.

［38］ UNVERDORBEN M，KLEBER F X，HEUER H，et al.Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCADⅠ study：are lesions clinically stable from 12 to 36 months?［J］.EuroIntervention，2013，9（5）：620-628.

［39］ LATIB A，COLOMBO A，CASTRIOTA F，et al.A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels：the BELLO（Balloon Elution and Late Loss Optimization） study［J］.J Am Coll Cardiol，2012，60（24）：2473-2480.

［40］ NAGANUMA T，LATIB A，SGUEGLIA G A，et al.A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study［J］.Int J Cardiol，2015，184 ：17-21.

［41］ SCHULZ A，HAUSCHILD T，KLEBER F X.Treatment of coronary de novo bifurcation lesions with DCB only strategy［J］.Clin Res Cardiol，2014，103（6）：451-456.

［42］ STELLA P R，BELKACEMI A，DUBOIS C，et al.A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drugeluting stent in bifurcation lesions treated with a single-stenting technique：six-month angiographic and 12-month clinical results of the drug eluting balloon in bifurcations trial［J］.Catheter Cardiovasc Interv，2012，80（7）：1138-1146.

［43］ ALI R M，DEGENHARDT R，ZAMBAHARI R，et al.Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxeleluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus［J］.EuroIntervention，2011，7 Suppl K：K83-K92.

［44］ BELKACEMI A，AGOSTONI P，NATHOE H M，et al.First results of the DEB-AMI（Drug Eluting Balloon in Acute ST-Segment Elevation Myocardial Infarction） trial：a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic，intravascular，functional，and clinical outcomes［J］.J Am Coll Cardiol，2012，59（25）：2327-2337.

［45］ ITO R，UENO K，YOSHIDA T，et al.Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions［J］.J Interv Cardiol，2018，31（4）：436-441.

［46］ WÖHRLE J，WERNER G S.Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries［J］.Catheter Cardiovasc Interv，2013，81（5）：793-799.